CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 133 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q3 2020. The put-call ratio across all filers is 0.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $85,000 | +57.4% | 43,200 | 0.0% | 0.00% | – |
| Q4 2020 | $54,000 | -66.0% | 43,200 | -51.1% | 0.00% | – |
| Q3 2020 | $159,000 | -85.6% | 88,300 | -33.1% | 0.00% | -100.0% |
| Q2 2020 | $1,107,000 | +60.7% | 132,000 | +0.4% | 0.00% | – |
| Q1 2020 | $689,000 | +43.8% | 131,500 | +49.8% | 0.00% | – |
| Q4 2019 | $479,000 | +11.9% | 87,800 | 0.0% | 0.00% | – |
| Q3 2019 | $428,000 | -29.6% | 87,800 | 0.0% | 0.00% | – |
| Q2 2019 | $608,000 | -0.3% | 87,800 | 0.0% | 0.00% | – |
| Q1 2019 | $610,000 | +15.5% | 87,800 | -2.9% | 0.00% | – |
| Q4 2018 | $528,000 | +26.3% | 90,400 | +63.2% | 0.00% | – |
| Q3 2018 | $418,000 | +141.6% | 55,400 | +61.5% | 0.00% | – |
| Q2 2018 | $173,000 | +1.8% | 34,300 | +23.4% | 0.00% | – |
| Q1 2018 | $170,000 | +57.4% | 27,800 | +82.9% | 0.00% | – |
| Q4 2017 | $108,000 | +36.7% | 15,200 | +38.2% | 0.00% | – |
| Q3 2017 | $79,000 | +14.5% | 11,000 | 0.0% | 0.00% | – |
| Q2 2017 | $69,000 | – | 11,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knoll Capital Management, LLC | 3,738,925 | $23,555,000 | 31.22% |
| Perceptive Advisors | 1,232,500 | $7,764,000 | 0.39% |
| IFP Advisors, Inc | 1,001,025 | $6,306,000 | 0.27% |
| WOODSTOCK CORP | 55,489 | $350,000 | 0.07% |
| Virtus ETF Advisers LLC | 50,795 | $320,000 | 0.05% |
| Dynamic Technology Lab Private Ltd | 31,431 | $198,000 | 0.04% |
| Evanson Asset Management, LLC | 20,660 | $130,000 | 0.03% |
| Artal Group S.A. | 250,000 | $1,575,000 | 0.03% |
| GSA CAPITAL PARTNERS LLP | 58,800 | $370,000 | 0.02% |
| Raymond James Financial Services Advisors, Inc. | 426,280 | $2,686,000 | 0.02% |